nCino, Inc.
16.2.2026 13:30:00 CET | Globenewswire | Press release
nCino Announces Timing of its Fourth Quarter Fiscal Year 2026 Financial Results Conference Call
nCino Announces Timing of its Fourth Quarter Fiscal Year 2026 Financial Results Conference Call
WILMINGTON, N.C., Feb. 16, 2026 (GLOBE NEWSWIRE) -- nCino, Inc. (NASDAQ: NCNO), the leading provider of intelligent, best-in-class banking solutions, will report financial results for its fourth quarter ended January 31, 2026, after the market close on Tuesday, March 31, 2026. nCino will host a conference call and webcast that day at 4:30 p.m. ET to discuss its financial results.
Event: nCino’s Fourth Quarter Fiscal Year 2026 Financial Results Conference Call
Date and Time: Tuesday, March 31, 2026 at 4:30 p.m. ET
Webcast Link: https://investor.ncino.com/
Replay: A webcast replay will be available on the Investor Relations section of nCino’s website following the call.
About nCino
nCino (NASDAQ: NCNO) is powering a new era in financial services. The Company was founded to help financial institutions digitize and reengineer business processes to boost efficiencies and create better banking experiences. With over 2,700 customers worldwide - including community banks, credit unions, independent mortgage banks, and the largest financial entities globally - nCino offers a trusted platform of best-in-class, intelligent solutions. By integrating artificial intelligence and actionable insights into its platform, nCino is helping financial institutions consolidate legacy systems to enhance strategic decision-making, improve risk management, and elevate customer satisfaction by cohesively bringing together people, AI and data. For more information, visit www.ncino.com.
CONTACTS
INVESTOR CONTACT
investor@ncino.com
MEDIA CONTACT
press@ncino.com
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Genmab A/S13.6.2026 18:45:00 CEST | Press release
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
King Faisal Specialist Hospital & Research Centre13.6.2026 15:57:00 CEST | Press release
KFSH Showcases Trusted AI as the Foundation for Scalable Healthcare Transformation at HLTH Europe 2026
Chery Group13.6.2026 11:39:45 CEST | Press release
FREELANDER 8 Makes First Public Appearance Ahead of Official Abu Dhabi Launch
Hotel Belles Rives13.6.2026 00:11:17 CEST | Press release
Julian Barnes Named Laureate of the 2026 Fitzgerald Prize
Sanofi Winthrop Industrie13.6.2026 00:09:43 CEST | Press release
Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom